- Home
- BTAI vs FSEA Comparison
BTAI vs FSEA Comparison
Compare BTAI & FSEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BTAI
- FSEA
- Stock Information
- Founded
- BTAI 2017
- FSEA 1890
- Country
- BTAI United States
- FSEA United States
- Employees
- BTAI N/A
- FSEA N/A
- Industry
- BTAI Biotechnology: Pharmaceutical Preparations
- FSEA Savings Institutions
- Sector
- BTAI Health Care
- FSEA Finance
- Exchange
- BTAI Nasdaq
- FSEA Nasdaq
- Market Cap
- BTAI 52.7M
- FSEA 53.7M
- IPO Year
- BTAI 2018
- FSEA N/A
- Fundamental
- Price
- BTAI $3.01
- FSEA $11.49
- Analyst Decision
- BTAI Buy
- FSEA
- Analyst Count
- BTAI 5
- FSEA 0
- Target Price
- BTAI $32.80
- FSEA N/A
- AVG Volume (30 Days)
- BTAI 5.2M
- FSEA 2.4K
- Earning Date
- BTAI 11-13-2025
- FSEA 11-07-2025
- Dividend Yield
- BTAI N/A
- FSEA N/A
- EPS Growth
- BTAI N/A
- FSEA N/A
- EPS
- BTAI N/A
- FSEA N/A
- Revenue
- BTAI $868,000.00
- FSEA $14,095,000.00
- Revenue This Year
- BTAI N/A
- FSEA N/A
- Revenue Next Year
- BTAI $614.78
- FSEA N/A
- P/E Ratio
- BTAI N/A
- FSEA N/A
- Revenue Growth
- BTAI N/A
- FSEA 30.26
- 52 Week Low
- BTAI $1.17
- FSEA $8.90
- 52 Week High
- BTAI $13.28
- FSEA $11.95
- Technical
- Relative Strength Index (RSI)
- BTAI 41.66
- FSEA 48.68
- Support Level
- BTAI $2.86
- FSEA $11.37
- Resistance Level
- BTAI $3.95
- FSEA $11.61
- Average True Range (ATR)
- BTAI 0.34
- FSEA 0.12
- MACD
- BTAI -0.17
- FSEA -0.02
- Stochastic Oscillator
- BTAI 11.89
- FSEA 20.28
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
About FSEA First Seacoast Bancorp Inc.
First Seacoast Bancorp Inc is a savings and loan holding company. Its business consists of taking deposits from the general public and investing those deposits, together with funds generated from operations and borrowings from the Federal Home Loan Bank, in one-to-four-family residential real estate loans, commercial real estate, and multi-family real estate loans, acquisition, development and land loans, commercial and industrial loans, home equity loans and lines of credit and consumer loans. The company generates revenue from financial instruments, such as loans, letters of credit, and investment securities, as well as revenue related to mortgage servicing activities, and bank-owned life insurance.